Inotec AMD, a fast-growing medtech business that has developed an innovative device to heal and treat complex chronic wounds, has secured £7m in a funding round led by Praetura Ventures.  The business has developed Natrox, a cutting-edge product that uses pure humidified oxygen to treat a range of chronic wounds, from diabetic and venous ulcers to non-healing surgical wounds. Following several successful clinical trials, Inotec AMD is looking to expand its foothold in the US, Asia, the Middle East and Europe. The business currently provides products to the NHS and health providers in key markets including the US, Italy, Southeast Asia and the Middle East.